Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
AssigneeNeuren Pharmaceuticals Limited
InventorsPeter David Gluckman, Gregory Brian Thomas, Jian Guan, Michael Dragunow, Ashmit Kumar Anand, Frank Sieg, Margaret Anne Brimble
Life of this patent
Estimating the term…
Abstract
This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.
Claims13
A method of treating an animal having a neurological injury caused by traumatic brain injury, comprising administration to an animal in need thereof a therapeutically effective amount of glycyl-L-2-methyl prolyl-L-glutamic acid (G-2MePE) to provide relief from a symptom of said traumatic brain injury.
A method for reducing a seizure induced by traumatic brain injury comprising administering to an animal in need thereof a pharmacologically effective amount of G-2MePE.
Dependencies are inferred from the claim text.